Literature Review:
AFOI patients receiving Dexmeditomidine and with Mallampati Class IV
airways required significantly less intravenous midazolam rescue
sedation than placebo users (33.3 percent [4/12] vs. 91.7 percent
[11/12]; p0.001), compared to placebo recipients. In all surgical
subtypes except breast biopsies, excision of lesions, and plastic
surgery, both Dexmeditomidine treatment groups and placebo treatment
groups demonstrated statistically significant (p-values not reported)
differences in the percentage of patients who did not require
intravenous midazolam rescue sedation during MAC, with the exception of
breast biopsies, excision of lesions, and plastic surgery, where no
statistically significant difference between the Dexmeditomidine
treatment groups and placebo.